Cited by 1,249Venous Thromboembolism Diagnosis and ManagementBlood Coagulation and Thrombosis MechanismsCerebral Venous Sinus Thrombosis

The DOI matches its Crossref record; 205 of the 208 references it cites were found in a registry or an index.

Antithrombotic Therapy for Venous Thromboembolic Disease

Büller, Harry R., Agnelli, Giancarlo, Hull, Russel D., Hyers, Thomas M., Prins, Martin H., Raskob, Gary E.·2004·Chest

DOI 10.1378/chest.126.3_suppl.401s

Open this paper in CoChat — free account

Abstract

This chapter about antithrombotic therapy for venous thromboembolic disease is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S-187S). Among the key recommendations in this chapter are the following: for patients with objectively confirmed deep vein thrombosis (DVT), we recommend short-term treatment with subcutaneous (SC) low molecular weight heparin (LMWH) or, alternatively, IV unfractionated heparin (UFH) [both Grade 1A]. For patients with a high clinical suspicion of DVT, we recommend treatment with anticoagulants while awaiting the outcome of diagnostic tests (Grade 1C+). In acute DVT, we recommend initial treatment with LMWH or UFH for at least 5 days (Grade 1C), initiation of vitamin K antagonist (VKA) together with LMWH or UFH on the first treatment day, and discontinuation of heparin when the international normalized ratio (INR) is stable and > 2.0 (Grade 1A). For the duration and intensity of treatment for acute DVT of the leg, the recommendations include the following: for patients with a first episode of DVT secondary to a transient (reversible) risk factor, we recommend long-term treatment with a VKA for 3 months over treatment for shorter periods (Grade 1A). For patients with a first episode of idiopathic DVT, we recommend treatment with a VKA for at least 6 to 12 months (Grade 1A). We recommend that the dose of VKA be adjusted to maintain a target INR of 2.5 (INR range, 2.0 to 3.0) for all treatment durations (Grade 1A). We recommend against high-intensity VKA therapy (INR range, 3.1 to 4.0) [Grade 1A] and against low-intensity therapy (INR range, 1.5 to 1.9) compared to INR range of 2.0 to 3.0 (Grade 1A). For the prevention of the postthrombotic syndrome, we recommend the use of an elastic compression stocking (Grade 1A). For patients with objectively confirmed nonmassive PE, we recommend acute treatment with SC LMWH or, alternatively, IV UFH (both Grade 1A). For most patients with pulmonary embolism (PE), we recommend clinicians not use systemic thrombolytic therapy (Grade 1A). For the duration and intensity of treatment for PE, the recommendations are similar to those for DVT.

Integrity signals

Registry

Crossref · 10.1378/chest.126.3_suppl.401s

Cites

205 of 205 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer
Lee, A. Y. Y., Levine, M. N., Baker, R. I., Bowden, C., Kakkar, A. K., Prins, M. H., Rickles, F. R., Julian, J. A., Haley, S., Kovacs, M. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025313 · Cited by 2,528
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,094
A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis
Decousus, H., Leizorovicz, A., Parent, F., Page, Y., Tardy, B., Girard, P., Laporte, S., Faivre, R., Charbonnier, B., Barral, F.-G., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802123380701 · Cited by 1,702
The management of thrombosis in the antiphospholipid-antibody syndrome
Khamashta, M. A., Cuadrado, M. J., Mujic, F., Taub, N. A., Hunt, B. J., & Hughes, G. R. V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321504 · Cited by 1,450
ANTICOAGULANT DRUGS IN THE TREATMENT OF PULMONARY EMBOLISM
Barritt, D. W., & Jordan, S. C. (1960) · The Lancet · doi:10.1016/s0140-6736(60)92299-6 · Cited by 1,362
Predictors of Recurrence After Deep Vein Thrombosis and Pulmonary Embolism
Heit, J. A., Mohr, D. N., Silverstein, M. D., Petterson, T. M., O’Fallon, W. M., & Melton, L. J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.6.761 · Cited by 1,348
A Comparison of Low-Molecular-Weight Heparin Administered Primarily at Home with Unfractionated Heparin Administered in the Hospital for Proximal Deep-Vein Thrombosis
Levine, M., Gent, M., Hirsh, J., Leclerc, J. E., Anderson, D. R., Weitz, J. I., Ginsberg, J. S., Turpie, A. G. G., Demers, C., Kovacs, M. J., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341101 · Cited by 1,186
Hemorrhagic Complications of Anticoagulant Treatment
Levine, M. N., Raskob, G. E., Landefeld, S., & Kearon, C. (2001) · CHEST Journal · doi:10.1378/chest.119.1_suppl.108s · Cited by 1,129
Treatment of Venous Thrombosis with Intravenous Unfractionated Heparin Administered in the Hospital as Compared with Subcutaneous Low-Molecular-Weight Heparin Administered at Home
Koopman, M. M. W., Prandoni, P., Piovella, F., Ockelford, P., Brandjes, D. P. M., van der Meer, J., Gallus, A. S., Simonneau, G., Chesterman, C., Prins, M. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341102 · Cited by 1,105
A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous Thromboembolism
Kearon, C., Gent, M., Hirsh, J., Weitz, J. I., Kovacs, M. J., Anderson, D. R., Turpie, A. G. G., Green, D., Ginsberg, J. S., Wells, P. S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,057

Show all 208 references

Research works printed but not linked: 7

Hull, 2002, A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium [abstract], Blood, 100, 148a
Hull, 2001, Safety and efficacy results for a study investigating the long-term out-of-hospital treatment of patients with proximal-vein thrombosis using subcutaneous low-molecular-weight heparin versus warfarin [abstract], Thromb Haemost
Hull, 2003, A randomised trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in patients with current cancer [abstract], Thromb Haemost, P137a
Prandoni, 2002, Below-knee compression stockings for prevention of the post-thrombotic syndrome: a randomized study [abstract], Pathophysiol Haemost Thromb, 32, 72
Morl, 1986, Treatment of postthrombotic syndrome with a mixture of enzymes [in German], Therapiewoche, 36, 2443
Massoure, 2000, Thromboses veineuses profondes des members supérieurs, J Mal Vasc, 25, 250
Pegis, 1997, Thrombolyse in situ dans le traitement des thromboses veineuses d'effort du membre supérieur, J Mal Vasc, 22, 187

Sorted by citations

Items 301–400 of 1,000

Arterial pulmonary hypertension in noncardiac intensive care unit
Tsapenko, M. V. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3998 · Cited by 43
“…associated hemodynamic instability or cardiogenic/obstructive shock aims at urgently relieving mechanical obstruction of the pulmonary circulation by either pharmacologic thrombolysis or by surgical or catheter thrombectomy (or mechanical clot disruption) (Buller et al 2004; Yoshida et al 2006).”
Multicenter evaluation of a new quantitative highly sensitive D-dimer assay, the Hemosil® D-dimer HS 500, in patients with clinically suspected venous thromboembolism
Legnani, C., Cini, M., Scarvelis, D., Toulon, P. A., Wu, J. R., & Palareti, G. (2009) · Thrombosis Research · doi:10.1016/j.thromres.2009.07.013 · Cited by 43
Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism
Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galiè, N., Pruszczyk, P., Bengel, F. M., Brady, A. J. B., Ferreira, D., Janssens, U., et al. (2008) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(09)60060-8 · Cited by 43
The Efficacy of Rotational Thrombectomy on the Mortality of Patients with Massive and Submassive Pulmonary Embolism
Dumantepe, M., Teymen, B., Aktürk, Ü. A., & Seren, M. (2015) · Journal of Cardiac Surgery · doi:10.1111/jocs.12521 · Cited by 42
“The American College of Chest Physicians and the European Society of Cardiology have recommended thrombolytic therapy in MPE, although this is based only on 2B grade of evidence.(13) In fact, more recent evidence has not been able to confirm a benefit with thrombolysis; a similar death rate was found in patients with…”
Method
How Frequently Is Venous Thromboembolism in Heparin-Treated Patients Associated With Heparin-Induced Thrombocytopenia?
Levine, R. L., McCollum, D. A., & Hursting, M. J. (2006) · CHEST Journal · doi:10.1378/chest.130.3.681 · Cited by 42
Prognostic role of the controlling nutritional status score in acute ischemic stroke among stroke subtypes
Naito, H., Hosomi, N., Nezu, T., Kuzume, D., Aoki, S., Morimoto, Y., Yoshida, T., Shiga, Y., Kinoshita, N., Ueno, H., et al. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116984 · Cited by 41
Long-duration temporary vena cava filter: A prospective 104-case multicenter study
Bovyn, G., Ricco, J., Reynaud, P., & Blanche, A. F. L. (2006) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2006.02.004 · Cited by 41
Retrievable vena cava filters: a review
Imberti, D., Ageno, W., & Carpenedo, M. (2006) · Current Opinion in Hematology · doi:10.1097/01.moh.0000239707.63168.ee · Cited by 41
Acute pulmonary embolism
Tapson, V. F. (2004) · Cardiology Clinics · doi:10.1016/j.ccl.2004.04.002 · Cited by 42
Prospective implementation of an algorithm for bedside intravascular ultrasound-guided filter placement in critically ill patients
Killingsworth, C., Taylor, S. M., Patterson, M. A., Weinberg, J. A., McGwin, G., Melton, S. M., Reiff, D. A., Kerby, J. D., Rue, L. W., Jordan, W. D., et al. (2010) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2009.12.041 · Cited by 40
Safety and Efficacy of Percutaneous Nephrostolithotomy in Patients on Anticoagulant Therapy
Kefer, J. C., Turna, B., Stein, R. J., & Desai, M. M. (2008) · The Journal of Urology · doi:10.1016/j.juro.2008.09.008 · Cited by 40
Combined use of clinical pretest probability and D‐dimer test in cancer patients with clinically suspected deep venous thrombosis
Nisio, M. D., Rutjes, A. W., & Buller, H. R. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01671.x · Cited by 40
Individualized Compared With Conventional Dosing of Enoxaparin
Barras, M. A., Duffull, S. B., Atherton, J. J., & Green, B. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100399 · Cited by 40
Solid cancer, antiphospholipid antibodies, and venous thromboembolism☆
Font, C., Vidal, L., Espinosa, G., Tàssies, D., Monteagudo, J., Farrus, B., Visa, L., Cervera, R., Gascón, P., & Reverter, J. C. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2010.10.006 · Cited by 40
“Anticoagulant therapy was prescribed according to the current international recommendations during the study period [27,28] including clinical evidence from the CLOT study [29].”
Method
Thrombophilias—Practical Implications and Testing Caveats
Moll, S. (2006) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-006-5570-0 · Cited by 40
“However, current recommendations for length of oral anticoagulation after a first thrombotic event are the same whether the patient has heterozygous factor V Leiden or not [3].”
Background
Therapy Insight: venous-catheter-related thrombosis in cancer patients
Agnelli, G., & Verso, M. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0458 · Cited by 40
Venous thromboembolism in neonates and children
Kenet, G., & Nowak‐Göttl, U. (2012) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2012.07.001 · Cited by 40
“Whether long-term continuation of anticoagulant treatment should be considered after a first VTE in carriers of a thrombophilic trait is still a matter of debate [100,101].”
Background
Pulmonary hypertension in critical care
Gayat, É., & Mebazaa, A. (2011) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32834a7619 · Cited by 40
Current practise of testing for inherited thrombophilia
Coppens, M., van MOURIK, J. A., Eckmann, C. M., Buller, H. R., & Middeldorp, S. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02658.x · Cited by 40
Diagnosis and management of people with venous thromboembolism and advanced cancer: how do doctors decide? a qualitative study
Johnson, M. J., Sheard, L., Maraveyas, A., Noble, S., Prout, H., Watt, I. S., & Dowding, D. (2012) · BMC Medical Informatics and Decision Making · doi:10.1186/1472-6947-12-75 · Cited by 40
“Three randomised controlled trials have demonstrated low molecular weight heparin (LMWH) to be superior to warfarin in the management of cancer associated thrombosis (CAT) and LMWH is now recommended as the anticoagulant of choice in patients with malignant disease [9,11,12,14-18].”
Background
Imaging of deep vein thrombosis
Orbell, J., Smith, A., Burnand, K. G., & Waltham, M. (2008) · British journal of surgery · doi:10.1002/bjs.6077 · Cited by 39
Contrast enhanced pulmonary magnetic resonance angiography for pulmonary embolism: Building a successful program
Nagle, S. K., Schiebler, M. L., Repplinger, M. D., François, C. J., Vigen, K. K., Yarlagadda, R., Grist, T. M., & Reeder, S. B. (2015) · European Journal of Radiology · doi:10.1016/j.ejrad.2015.12.018 · Cited by 39
Computed tomography for pulmonary embolism: assessment of a 1-year cohort and estimated cancer risk associated with diagnostic irradiation
Niemann, T., Zbinden, I., Roser, H. W., Bremerich, J., Rémy-Jardin, M., & Bongartz, G. M. (2013) · Acta Radiologica · doi:10.1177/0284185113485069 · Cited by 39
Venous thromboembolism in cervical cancer
Barbera, L. C., & Thomas, G. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70409-6 · Cited by 38
Cationic derivative of dextran reverses anticoagulant activity of unfractionated heparin in animal models of arterial and venous thrombosis
Kałaska, B., Sokołowska, E., Kamiński, K., Szczubiałka, K., Kramkowski, K., Mogielnicki, A., Nowakowska, M., & Buczko, W. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.04.037 · Cited by 37
“However, unfractionated heparin is still used in the treatment of acute coronary syndrome, atrial fibrillation, deep-vein thrombosis, hemofiltration and cardiopulmonary bypass for heart surgery (Antman et al., 2004; Braunwald et al., 2002; Buller et al., 2004; Geerts et al., 2004).”
Background
A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants
Ghanim, A. J., Daskalakis, C., Eschelman, D. J., & Kraft, W. K. (2007) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-007-0025-9 · Cited by 38
“In cases where full dose anticoagulation is problematic due to either active bleeding or a high risk of major bleeding, inferior vena cava filters (IVCF) are often employed to prevent embolization to the lung [10, 11].”
Background
Cerebral Venous and Sinus Thrombosis
Einhäupl, K. M., Bousser, M., de Bruijn, S. F. T. M., Ferro, J. M., Martinelli, I., Masuhr, F., & Stam, J. (2006) · doi:10.1002/9780470753279.ch37 · Cited by 38
Evidence Base for the Management of Venous Thromboembolism in Pregnancy
Rodger, M. A. (2010) · Hematology · doi:10.1182/asheducation-2010.1.173 · Cited by 37
Neurologic manifestations of the antiphospholipid syndrome: Integrating molecular and clinical lessons
Muscal, E., & Brey, R. L. (2008) · Current Rheumatology Reports · doi:10.1007/s11926-008-0012-y · Cited by 37
“Expert opinions recommend indefinite oral anticoagulation due to prevalent thrombosis recurrence rates [ 32 ].”
Background
Retrievable vena cava filters: Key considerations
Imberti, D., & Prisco, D. (2007) · Thrombosis Research · doi:10.1016/j.thromres.2007.06.017 · Cited by 36
No effect of epoprostenol on right ventricular diameter in patients with acute pulmonary embolism: a randomized controlled trial
Kooter, A. J., IJzerman, R. G., Otto Kamp, B., Boonstra, A., & Smulders, Y. M. (2010) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-10-18 · Cited by 36
“Therefore, treatment focusses on relieving mechanical obstruction, either by anticoagulation if patients are stable, or by thrombolytic therapy in case of hemodynamic instability [4].”
Background
Heparin, Low Molecular Weight Heparin, and Derivatives in Thrombosis, Angiogenesis, and Inflammation: Emerging Links
Mousa, S. A. (2007) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-2007-982084 · Cited by 36
“Heparin and Venous Thromboembolism The large majority of patients with venous thromboembolism (VTE) currently are treated with full doses of UFH or LMWH, followed by at least 3 months of oral anticoagulant therapy.(15) Selected patients with critical manifestations of pulmonary embolism (PE) are administered thromboly…”
Thrombomodulin as a Marker for Bleeding Complications During Warfarin Treatment
Lind, M. M., Boman, K., Johansson, L., Nilsson, T. K., Öhlin, A.-K., Birgander, L. S., & Jansson, J.-H. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.170 · Cited by 36
Need for Inferior Vena Cava Filters in Cancer Patients: A Surrogate Marker for Poor Outcome
Barginear, M. F., LESSER, M. L., Akerman, M. B., Strakhan, M., Shapira, I., Bradley, T. P., & Budman, D. R. (2008) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029608315165 · Cited by 36
“Before low-molecular-weight heparin became standard of care in cancer patients with a VTE, warfarin was used.(27) Patients with cancer and thrombosis treated with warfarin have an increased risk of recurrent thrombosis and bleeding while on full AC with therapeutic international normalized ratio (INR).”
Background
Comparative Performance of Three Anti-Factor Xa Heparin Assays in Patients in a Medical Intensive Care Unit Receiving Intravenous, Unfractionated Heparin
Lehman, C. M., Rettmann, J. A., Wilson, L. W., & Markewitz, B. A. (2006) · American Journal of Clinical Pathology · doi:10.1309/8e3u7rxepxnp27r7 · Cited by 36
Guidelines and the use of inferior vena cava filters: a review of an institutional experience
SINGH, P., LAI, H. M., LERNER, R. G., Chugh, T., & Aronow, W. S. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03217.x · Cited by 36
Society of Interventional Radiology Position Statement: Treatment of Acute Iliofemoral Deep Vein Thrombosis with Use of Adjunctive Catheter-directed Intrathrombus Thrombolysis
Vedantham, S., Millward, S. F., Cardella, J. F., Hofmann, L. V., Razavi, M. K., Grassi, C. J., Sacks, D., & Kinney, T. B. (2009) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2009.04.017 · Cited by 36
A prospective observational study of IVC filters in pediatric patients
Raffini, L. J., Cahill, A. M., Hellinger, J. C., & Manno, C. S. (2008) · Pediatric Blood & Cancer · doi:10.1002/pbc.21622 · Cited by 36
“Current guidelines for IVC filter placement include the presence of venous thromboembolism (VTE) and a contraindication to anticoagulation, proven VTE and a complication from anticoagulation, or recurrent VTE despite adequate anticoagulation [2].”
Background
Association of Bleeding and In-Hospital Mortality in Black and White Patients With ST-Segment–Elevation Myocardial Infarction Receiving Reperfusion
Mehta, R. H., Parsons, L. S., Rao, S. V., & Peterson, E. D. (2012) · Circulation · doi:10.1161/circulationaha.111.068668 · Cited by 35
Controversies in venous thromboembolism: to treat or not to treat superficial vein thrombosis
Beyer‐Westendorf, J. (2017) · Hematology · doi:10.1182/asheducation-2017.1.223 · Cited by 35
Venous thromboembolism: diagnosis and management of pulmonary embolism
Lee, C. H., Hankey, G. J., Ho, W. K., & Eikelboom, J. W. (2005) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2005.tb06816.x · Cited by 35
Superficial Thrombophlebitis of the Lower Limb: Practical Recommendations for Diagnosis and Treatment
Maeseneer, M. G. D. (2005) · Acta chirurgica Belgica · doi:10.1080/00015458.2005.11679688 · Cited by 34
Management and treatment of deep vein thrombosis in special populations
Boon, G., van Dam, L. F., Klok, F. A., & Huisman, M. V. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1502082 · Cited by 34
“LMWH as preferred treatment of cancer-associated VTE since 2004 [13].”
Background
Thrombosis associated with right internal jugular central venous catheters: A prospective observational study
Kujur, R., Badwaik, G., & Paraswani, R. (2012) · Indian Journal of Critical Care Medicine · doi:10.4103/0972-5229.94419 · Cited by 34
Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice
Cárdenas, M. J. S., Pelayo-García, G., Rodríguez-Camacho, A., Segura-Fernandez, E., Mogollo, A., & González, J. A. G. (2008) · Palliative Medicine · doi:10.1177/0269216308098803 · Cited by 34
Management of Venous Thromboembolism in the Elderly
Spyropoulos, A. C., & Merli, G. J. (2006) · Drugs & Aging · doi:10.2165/00002512-200623080-00003 · Cited by 33
Usefulness of cardiac biomarkers in the prediction of right ventricular dysfunction before echocardiography in acute pulmonary embolism
Choi, H. S., Kim, K. H., Yoon, H. J., Hong, Y. J., Kim, J. H., Ahn, Y., Jeong, M. H., Cho, J. G., Park, J. C., & Kang, J. C. (2012) · Journal of Cardiology · doi:10.1016/j.jjcc.2012.07.006 · Cited by 34
The headache over warfarin in British neurosurgical intensive care units: a national survey of current practice
Appelboam, R., & Thomas, E. (2007) · Intensive Care Medicine · doi:10.1007/s00134-007-0765-1 · Cited by 34
Antithrombotic therapy in children
Chalmers, E. A., & Bonduel, M. M. (2005) · Progress in Pediatric Cardiology · doi:10.1016/j.ppedcard.2005.09.005 · Cited by 34
Upper Extremity Venous Doppler Ultrasound
Weber, T. M., Lockhart, M. E., & Robbin, M. L. (2007) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2007.04.005 · Cited by 34
Venous thromboembolic disease and cancer
Fennerty, A. G. (2006) · Postgraduate Medical Journal · doi:10.1136/pgmj.2006.046987 · Cited by 33
Safety of Inferior Vena Cava Filter Retrieval in Anticoagulated Patients
Hoppe, H., Kaufman, J. A., Barton, R. E., Petersen, B. D., Lakin, P. C., DeLoughery, T. G., Irani, Z., Yavuz, K., & Keller, F. S. (2007) · CHEST Journal · doi:10.1378/chest.06-2897 · Cited by 33
Effectiveness of a Guideline for Venous Thromboembolism Prophylaxis in Elderly Post–Acute Care Patients
Sellier, É. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2065 · Cited by 33
“As a result, most randomized controlled trials of thromboprophylaxis rely on a composite end point, combining proximal and distal DVTs,(17) and published guidelines recommend treating patients with thrombosis confined to the deep veins of the calf with an anticoagulant agent for 3 months.(30) In our study, the decreas…”
Background
Characterization of the Proportion of Untreated and Antiplatelet Therapy Treated Patients With Atrial Fibrillation
Ogilvie, I. M., Welner, S. A., Cowell, W., & Lip, G. Y. H. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.02.353 · Cited by 32
Is Deep Vein Thrombosis a Good Proxy for Pulmonary Embolus?
Parvizi, J., Jacovides, C. L., Bican, O., Purtill, J. J., Sharkey, P. F., Hozack, W. J., & Rothman, R. H. (2010) · The Journal of Arthroplasty · doi:10.1016/j.arth.2010.05.001 · Cited by 32
“Patients on long-term anticoagulants have a greater likelihood for developing bleeding disorders [8,9], requiring blood transfusions [8,10], or developing periprosthetic infections[8], and it has been suggested that potent anticoagulant drugs are associated with higher all-cause mortality rates after total hip and tot…”
Background
Tromboflebite superficial: epidemiologia, fisiopatologia, diagnóstico e tratamento
Sobreira, M. L., Yoshida, W. B., & Lastória, S. (2008) · Jornal Vascular Brasileiro · doi:10.1590/s1677-54492008000200007 · Cited by 35
How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review
Garcia, D. A., Khamashta, M. A., & Crowther, M. A. (2007) · Blood · doi:10.1182/blood-2006-10-041814 · Cited by 33
Anti-Xa Activity After Enoxaparin Prophylaxis In Hospitalized Patients Weighing Less Than Fifty-Five Kilograms
Rojas, L. E., Aizman, A., Ernst, D. M., Acuña, M. P., Moya, P., Mellado, R., & Jaime Cerda, L. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.10.005 · Cited by 32
“4 IU/ml [26,27].”
Antiphospholipid antibiodies: a critical review of the literature
Lim, W., & Crowther, M. A. (2007) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3282a4a65f · Cited by 32
Multidetector computed tomography for the diagnosis of acute pulmonary embolism
Stein, P. D., & Hull, R. D. (2007) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e32821acdbe · Cited by 32
The predictive factors of recurrent deep vein thrombosis.
Farzamnia, H., Rabiei, K., Sadeghi, M., & Roghani, F. (2011) · Europe PMC (PubMed Central) · Cited by 31
Retrievable vena cava filters: A clinical review
Tschoe, M., Kim, H. S., Brotman, D. J., & Streiff, M. B. (2009) · Journal of Hospital Medicine · doi:10.1002/jhm.439 · Cited by 31
Conundrums in the Combined Use of Anticoagulants and Antiplatelet Drugs
Schneider, D. J., & Sobel, B. E. (2007) · Circulation · doi:10.1161/circulationaha.106.655910 · Cited by 31
Vena Cava Filters: Current Concepts and Controversies for the Surgeon
Martin, M. J., Blair, K. S. A., Curry, T. K., & Singh, N. N. (2010) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2010.03.004 · Cited by 31
“5 mg/kg once a day.(69) Complications and concerns with LMWH nclude bleeding, hematoma at the administration site, HIT, decreased learance in renal failure, and the difficulty of full reversal of the nticoagulation effect.”
BackgroundInfluential
A descriptive evaluation of unfractionated heparin use during pregnancy
Clark, N. P., Delate, T., Witt, D. M., Parker, S., & McDuffie, R. S. (2008) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-008-0207-0 · Cited by 31
Ambulation and Compression After Deep Vein Thrombosis: Dispelling Myths
Partsch, H. (2005) · Seminars in Vascular Surgery · doi:10.1053/j.semvascsurg.2005.05.006 · Cited by 31
Günter Tulip Filter Retrieval Experience: Predictors of Successful Retrieval
Turba, U. C., Arslan, B., Meuse, M. A., Sabri, S. S., Macik, B. G., Hagspiel, K. D., Matsumoto, A. H., & Angle, J. F. (2009) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-009-9684-6 · Cited by 31
“Therefore, more randomized prospective clinical studies are needed to evaluate filter retrieval with larger patient populations [ 6 , 7]. Looby et al. [8] reported 80% successful retrieval in 45 patients at a mean of 34 days Ota et al. [9] reported 91% successful retrieval in 66 patients at a mean of 10 days.”
Background
The “parallel-cohort RCT”: Novel design aspects and application in the Kids-DOTT trial of pediatric venous thromboembolism
Goldenberg, N. A., Tripputi, M., Crowther, M. A., Abshire, T. C., DiMichele, D., Manco‐Johnson, M. J., & Hiatt, W. R. (2009) · Contemporary Clinical Trials · doi:10.1016/j.cct.2009.11.006 · Cited by 31
The Genomic Medicine Model: An Integrated Approach to Implementation of Family Health History in Primary Care
Orlando, L. A., Henrich, V. C., Hauser, E. R., Wilson, C., & Ginsburg, G. S. (2013) · Personalized Medicine · doi:10.2217/pme.13.20 · Cited by 31
Thrombophilia: Clinical and Laboratory Assessment and Management
Heit, J. A. (2007) · Elsevier eBooks · doi:10.1016/b978-141602401-9.10014-8 · Cited by 31
Drug Insight: antithrombotic therapy after percutaneous coronary intervention in patients with an indication for anticoagulation
Helft, G., Gilard, M., Feuvre, C. L., & Zaman, A. (2006) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0712 · Cited by 31
A cost analysis of the treatment of patients with post-thrombotic syndrome in Brazil
Ramacciotti, E., Gomes, M., de Aguiar, E. T., Caiafa, J. S., de Moura, L. K., de Araújo, G. R., Truzzi, A. C., & Dietrich-Neto, F. (2006) · Thrombosis Research · doi:10.1016/j.thromres.2005.12.005 · Cited by 31
Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders
Prandoni, P., Tormene, D., Perlati, M., Brandolin, B., & Spiezia, L. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.5.773 · Cited by 31
“The conventional treatment group in the van Gogh PE study clearly performed exceptionally well, compared to the same arm in the van Gogh DVT study and also compared to historical controls [18] .”
Result
Gains and losses of warfarin therapy as performed in an anticoagulation clinic
Njaastad, A. M., Abildgaard, U., & Lassen, J. F. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01605.x · Cited by 30
Ambulation after Deep Vein Thrombosis: A Systematic Review
Anderson, C. M., Overend, T. J., Godwin, J., Sealy, C., & Sunderji, A. (2009) · Physiotherapy Canada · doi:10.3138/physio.61.3.133 · Cited by 30
“This recommendation, graded as 1B in the 2004 guidelines, has been raised to a 1A recommendation in the most recent guidelines.(27,28) There have been two previous systematic reviews examining bed rest versus early mobilization.”
BackgroundMethod
Anticoagulation monitoring during vascular surgery: accuracy of the Hemochron ® low range activated clotting time (ACT-LR)
Tremey, B., Székély, B., Schlumberger, S., François, D., Liu, N., Sievert, K., & Fischler, M. (2006) · British Journal of Anaesthesia · doi:10.1093/bja/ael194 · Cited by 30
Warfarin initiation nomograms for venous thromboembolism
Lázaro, P. P. G., Ruiz, W., & Munarriz, C. A. L. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007699.pub3 · Cited by 30
Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT‑III: A pilot study
Zhang, L., Zhang, H., Zhang, J., Tian, H., Liang, J., & Liu, Z. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5471 · Cited by 31
“The primary exclusion criteria were as follows: Scr ≥3 mg/dl; requirement for thrombolytic therapy or inferior vena cava strainer implantation; risk of cerebral ischemia; intracerebral bleeding or gastrointestinal bleeding within the previous 6 months; surgery within the previous 4 weeks; an active peptic ulcer; a kno…”
Inferior Vena Caval Filters: Key Considerations
Failla, P. J., Reed, K. D., Karam, G. H., & Summer, W. R. (2005) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200508000-00005 · Cited by 30
Warfarin and the antiphospholipid syndrome: Does one size fit all?
Kasthuri, R. S., & Roubey, R. A. S. (2007) · Arthritis Care & Research · doi:10.1002/art.23111 · Cited by 30
Oral anticoagulation strategies after a first idiopathic venous thromboembolic event
Aujesky, D., Smith, K. J., & Roberts, M. S. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.02.018 · Cited by 29
Perioperative Management of Oral Anticoagulation
O'Donnell, M. J., & Kearon, C. (2008) · Cardiology Clinics · doi:10.1016/j.ccl.2007.12.012 · Cited by 29
Duration of Anticoagulation Therapy for Venous Thromboembolism
Bounameaux, H., & Perrier, A. (2008) · Hematology · doi:10.1182/asheducation-2008.1.252 · Cited by 31
Why should statins prevent venous thromboembolism? A systematic literature search and a call for action
Squizzato, A., Romualdi, E., & Ageno, W. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02030.x · Cited by 29
Statin use in patients with nephrotic syndrome is associated with a lower risk of venous thromboembolism
Resh, M., Mahmoodi, B. K., Navis, G. J., Veeger, N. J. G. M., & Lijfering, W. M. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2010.12.020 · Cited by 29
Applying Quality Measures and Guidelines in the Management of Acute Coronary Syndrome and Venous Thromboembolism
Gulseth, M. P., Sobieszczyk, P. S., Fanikos, J. R., & Seifert, R. D. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.s6-a.1 · Cited by 29
Venous thromboembolism in urologic surgery: prophylaxis, diagnosis, and treatment.
Rice, K. R., Brassell, S. A., & McLeod, D. G. (2010) · Europe PMC (PubMed Central) · Cited by 29
Lupus Anticoagulant Assays: Questions Answered and to Be Answered
Teruya, J., West, A., & Suell, M. N. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-885-laaqaa · Cited by 29
Outcomes for Inpatients with Normal Findings on Whole-leg Ultrasonography: A Prospective Study
Sevestre, M., Labarère, J., Casez, P., Bressollette, L., Haddouche, M., Pernod, G., Quéré, I., & Bosson, J. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.05.034 · Cited by 29
Valor pronóstico de los hallazgos electrocardiográficos en pacientes estables hemodinámicamente con tromboembolia de pulmón aguda sintomática
Escobar, C., Jiménez, D., Sánchez, D. M., Lobo, J. L., Díaz, G., Gallego, P., Vidal, R., Barrios, V., & Sueiro, A. (2008) · Revista Española de Cardiología · doi:10.1157/13116651 · Cited by 29
Pulmonary Vasodilators—Treating the Right Ventricle
Granton, J. T., & Moric, J. (2008) · Anesthesiology Clinics · doi:10.1016/j.anclin.2008.01.010 · Cited by 29
Low-Molecular-Weight Heparin and Survival in Patients with Malignant Disease
Kakkar, A. K. (2005) · Cancer Control · doi:10.1177/1073274805012003s05 · Cited by 29
Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA Study: ECONOMICS OF BEMIPARIN IN VENOUS THROMBOEMBOLISM
Santamaría, A., Juárez, S., Reche, A., Gómez-Outes, A., Martínez-González, J., Fontcuberta, J., & ON BEHALF OF THE ESFERA INVESTIGATORS (2006) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2006.00947.x · Cited by 28
Emergence of new oral antithrombotics: a critical appraisal of their clinical potential
Laux, V. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3266 · Cited by 28
“Anticoagulants are recommended for the prevention and treatment of venous thromboembolism (VTE), and the prevention of thromboembolic events in patients with chronic conditions such as atrial ﬁ brillation (AF) (Buller et al 2004; Geerts et al 2008), or in patients with mechanical heart valves.”
The Impact of an Aging Population on the Diagnosis of Pulmonary Embolism: Comparison of Young and Elderly Patients
Castelli, R., Bergamaschini, L. C., Sailis, P., Pantaleo, G., & Porro, F. (2007) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029607308860 · Cited by 29
Thromboembolic Diseases
Wakefield, T. W., Caprini, J. A., & Comerota, A. J. (2008) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2008.08.002 · Cited by 28
Long-term use of daily subcutaneous low molecular weight heparin in cancer patients with venous thromboembolism: why hesitate any longer?
Debourdeau, P., Elalamy, I., Raignac, A. D., MERIA, P., Gornet, J. M., Amah, Y., Korte, W., Marty, M. E., & Farge, D. (2008) · Supportive Care in Cancer · doi:10.1007/s00520-008-0491-4 · Cited by 28
“These data finally led the authors of the Italian (AIOM) [45], North American (ACPP and ASCO) [11, 44] and French (FNCLCC, www.”
Background
Thrombolysis for Pulmonary Embolism in Patients With Right Ventricular Dysfunction
Thabut, G., & Logeart, D. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.19.2200 · Cited by 28
“Despite the lack of definitive evidence,(3) massive PE associated with cardiogenic shock, given the high mortality rate, is a widely accepted indication for thrombolysis.(4,5) At the other extreme, the risks of thrombolysis are not justified in patients with an anatomically small PE that causes no elevation in RV afte…”
Background
Critical Care of the Obstetric Patient
Shapiro, J. M. (2006) · Journal of Intensive Care Medicine · doi:10.1177/0885066606290390 · Cited by 28
Acute pulmonary embolism revisited
Konstantinides, S. (2008) · Postgraduate Medical Journal · doi:10.1136/hrt.2005.071274 · Cited by 28

Authors: Büller, H. R., Agnelli, G., Hull, R. D., Hyers, T. M., Prins, M. H., & Raskob, G. E.
Venue: Chest
Publisher: Elsevier BV
Published: 2004-09
Volume: 126
Issue: 3
Pages: 401S-428S
ISSN: 0012-3692 (ISSN-L)
DOI: 10.1378/chest.126.3_suppl.401s
OpenAlex: W2134355273
Cited by: 1,249
References: 208
Citations by year: 2025: 4 · 2024: 2 · 2023: 2 · 2022: 7 · 2021: 8 · 2020: 9 · 2019: 13 · 2018: 15 · 2017: 17 · 2016: 32 · 2015: 25 · 2014: 25 · 2013: 41 · 2012: 54
FWCI: 121.06
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: CHEST Journal (publishedVersion)
PubMed (publishedVersion)
Pure Amsterdam UMC (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Topics: Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Health Sciences › Medicine › Clinical Neurology › Cerebral Venous Sinus Thrombosis
Keywords: venous thromboembolism, antithrombotic therapy, deep vein thrombosis, pulmonary embolism, low molecular weight heparin, unfractionated heparin, vitamin K antagonists, anticoagulation duration, post-thrombotic syndrome, compression stockings, thrombolysis, thromboprophylaxis
MeSH terms: Fibrinolytic Agents, Heparin, Heparin, Low-Molecular-Weight, Humans, Long-Term Care, Pulmonary Embolism, Vitamin K, Randomized Controlled Trials as Topic, Evidence-Based Medicine, International Normalized Ratio, Venous Thrombosis, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antithrombotic Therapy for Venous Thromboembolic Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks